Browse Category

Pharmaceuticals News 21 January 2026 - 23 January 2026

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson shares traded nearly flat at $218.59 by late Friday morning as Wall Street upgrades met renewed worries over federal talc lawsuits. A special master recommended allowing plaintiffs’ experts to testify that J&J talc products can cause ovarian cancer, affecting over 67,500 cases. The company reported Q4 sales up 9.1% to $24.6 billion and projected 2026 sales of up to $101 billion.
60 Degrees Pharmaceuticals stock swings again: SXTP slides in premarket after Runway Health deal pop

60 Degrees Pharmaceuticals stock swings again: SXTP slides in premarket after Runway Health deal pop

60 Degrees Pharmaceuticals shares fell 9.9% to $4.54 in Friday premarket trading, after soaring 152% the previous session on news of a Runway Health partnership to launch telehealth sales of its malaria pill ARAKODA starting April 2. The company executed a 1-for-4 reverse stock split on Jan. 20 to meet Nasdaq listing requirements.
India’s Q3 results rush: IndusInd Bank profit seen plunging as JSW Steel, BPCL, Cipla report today

India’s Q3 results rush: IndusInd Bank profit seen plunging as JSW Steel, BPCL, Cipla report today

Over 50 Indian companies, including IndusInd Bank, JSW Steel, BPCL, and Cipla, will report December-quarter earnings on Friday. Brokerages expect IndusInd Bank’s profit after tax to drop sharply, with forecasts ranging from 13 crore to 313 crore rupees. JSW Steel faces weaker prices, while BPCL may see higher EBITDA due to softer crude. Pharma and banking sectors remain under pressure.
60 Degrees Pharmaceuticals (SXTP) stock more than triples as Runway Health deal hits tape

60 Degrees Pharmaceuticals (SXTP) stock more than triples as Runway Health deal hits tape

Shares of 60 Degrees Pharmaceuticals (SXTP) jumped 267% to $7.34 Thursday after announcing a distribution deal with Runway Health for its malaria drug ARAKODA. Trading volume soared to nearly 116 million shares. The agreement will allow online consultations and home delivery starting April 2. A 1-for-4 reverse stock split took effect earlier this week.
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

AbbVie shares rose 0.4% to $214.92 by midday Wednesday after Berenberg raised its price target to $275. Bernstein maintained a Hold rating with a $225 target. Investors are watching for U.S. pharma tariff developments and AbbVie’s Feb. 4 earnings. The stock traded between $211.92 and $218.00 on volume of 5.3 million shares.
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals shares fell 8% to $19.68 in premarket trading Wednesday after announcing a $150 million stock-and-warrant offering. The drop follows a 167% surge Tuesday on positive Phase 1 data for soquelitinib in atopic dermatitis. Corvus paused its $100 million at-the-market share sales facility ahead of the new deal. No severe adverse events were reported in the trial.
1 9 10 11 12 13 56

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Go toTop